Avid Bioservices Inc (CDMO)

[biopharm]

excellent call....they are rephrasing, reiterating, and trying to get the point across that Bavi is a broad spectrum drug and their partnering discussions are not to just run a single ph III for NSCLC, but to expand the trials to the next set of trials to utilize Bavi in other solid tumors (means more upfront money)

I can see why that last medical conference was needed! just to get the medical ..oncology field... a detail on how Bavi works and I hope the interested BP's are listening and getting ready to make the deal because we're being drafted as the #1 pick this year!